Lv4
404 积分 2023-05-29 加入
[Guideline for HER2 detection in gastric cancer (2026 version)]
3天前
已完结
[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)]
11天前
已完结
[Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]
24天前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
24天前
已完结
尿路上皮癌抗HER2治疗中国专家共识（2026版）
24天前
已完结
[Guidelines on clinical practice of molecular tests in breast cancer in China (2025 edition)]
24天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
3个月前
已完结
Vebreltinib effective in MET-amplified NSCLC
3个月前
已完结
Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC
3个月前
已完结
Standardising MET amplification testing: limitations of the GCN ≥6 criterion
3个月前
已完结
皖公网安备34019202002308
